International Session (Symposium)1 (JSH, JSGE, JSGCS)

Lifestyle-related liver diseases: Elucidation of molecular mechanisms and development of new treatments

• Chairperson:
  Kazuhiko KoikeKanto Central Hospital
• Chairperson:
  Takahiro KodamaDepartment of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
• Discussant:
  Jacob GeorgeWestmead Hospital, University of Sydney
• Discussant:
  Akiko EguchiDepartment of Gastroenterology and Hepatology, Mie University Graduate School of Medicine

IS-S1-1_H
Hydroxynonenal causes hepatocyte death by lysosomal disintegrity in NAFLD.

IS-S1-2_H
Thrombospondin-2 is a novel biomarker for advanced fibrosis and potential therapeutic target in nonalcoholic fatty liver disease

IS-S1-3_H
p62/SQSTM1 in hepatocytes plays a protective role against the development of steatohepatitis in mice

IS-S1-4_H
Modulation of serotonin in the gut–liver neural axis ameliorates the progression of nonalcoholic fatty liver

IS-S1-5_H
Hepatocyte apoptosis links to decreased TET1 and 5-hydroxymethylcytosine formation: Possible role of α-Ketoglutarate in alcoholic and non-alcoholic fatty liver diseases

IS-S1-6_H
Discovery of a novel therapeutic agent for NAFLD derived from VDR-silent vitamin D derivatives

IS-S1-7_G
Effects of SGLT2 Inhibitor on the Progression and Metabolisms in Metabolism-Associated Liver Cancer: Multi-Omics Analysis of Metabolomics/Proteomics

IS-S1-8_H
NRF2 activator as dietary phytochemical against alcoholic liver disease-related fibrosis

International Session (Symposium)2 (JSH, JSGE)

Treatment and research for liver fibrosis - Current and future perspectives

• Chairperson:
  Yoshiyuki TakeiHonorary Professor, Mie University
• Chairperson:
  Goshi ShiotaDepartment of Genomic Medicine and Regenerative Therapeutics, Faculty of Medicine, Tottori University
• Discussant:
  Ekihiro SekiCedars-Sinai Medical Center
• Discussant:
  Yasuko Iwakiri Department of Internal Medicine, Section of Digestive Diseases, Yale School of Medicine

IS-S2-Keynote Lecture
The challenge to reverse liver fibrosis in advanced liver disease

IS-S2-1_H
Chitinase-3 like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis

IS-S2-2_G
NCX1/Ca²⁺ signal pathway contributes to the autophagy regulation during TGF-β-induced hepatic stellate cell activation

IS-S2-3_G
CTGF is an intercellular mediator to stimulate hepatic stellate cells and promote hepatic fibrosis. Young Award

IS-S2-4_G
Roles of CD8⁺ tissue-resident memory T cells in the liver fibrosis resolution

IS-S2-5_H
Fibrosis resolution involves more than collagen; key role of MMP12 in fibrosis recovery.

IS-S2-6_H
Anti-fibrosis application of overexpression and recombinant human CYGB in multiple models of advanced fibrosis

IS-S2-7_G
Therapeutic potential of chemically induced liver progenitor cells for liver fibrosis

International Session (Symposium)3 (JSH, JSGE, JSGS)

Advances in the treatment of the liver cancer: The state-of-the-art researches to provide the precision medicine and improve the prognosis

• Chairperson:
  Masatoshi KudoDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine
• Chairperson:
  Etsuro HatanoDivision of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University
• Discussant:
  Kaoru TsuchiyaDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital
• Discussant:
  Sadahisa OgasawaraDepartment of Gastroenterology, Graduate School of Medicine, Chiba University

IS-S3-Keynote Lecture
The state-of-art Lecture on the Treatment of Liver Cancer

IS-S3-1_H
The effectiveness of the locoregional treatment using hepatic arterial infusion chemotherapy for locally progressed hepatocellular carcinoma

IS-S3-2_G
The impact of molecular targeted therapies and the multidisciplinary management for survival of patients with advanced hepatocellular carcinoma

IS-S3-3_H
Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma

IS-S3-4_H
Exploring tumor microenvironment in patients with advanced hepatocellular carcinoma using needle biopsy samples Young Award

IS-S3-5_H
A new therapeutic strategy using cell-free DNA that predicts drug resistance of atezolizumab+bevacizumab for the treatment of advanced hepatocellular carcinoma.

IS-S3-Special Remarks

International Session (Symposium)4 (JGES, JSGE, JSGS)

New challenges for minimally invasive endoscopic treatment

• Chairperson:
  Hiroyuki OnoDivision of Endoscopy, Shizuoka Cancer Center
• Chairperson:
  Kazuki SumiyamaDepartment of Endoscopy, The Jikei University School of Medicine

IS-S4-Keynote Lecture
Endoscopic Treatment of Chronic Pancreatitis

IS-S4-1_E
Challenges and controversies in the assessment, prevention and therapy of post-POEM GERD

IS-S4-2_E
Endoluminal Robotics for Gastrointestinal Resection

IS-S4-3_E
Endoscopic sleeve gastroplasty for Japanese obese patients

IS-S4-4_G
Implementation of endoscopic full-thickness resection for gastric submucosal tumor into Japanese clinical practice Young Award

IS-S4-5_E
The study of utility and safety of colorectal full-thickness resection with laparoscopy and endoscopy cooperatively

IS-S4-6_E
Efficacy and safety of EFTR with port assistance for gastric GISTs

IS-S4-7_E
Current status and future perspectives of submucosal endoscopic surgeries for esophageal benign diseases

IS-S4-8_E
Innovative strategy for colorectal cancer with artificial intelligence

IS-S4-Special Remarks

International Session (Symposium)5 (JSGS, JSGE, JGES)

Minimally invasive surgery for hepato-biliary-pancreatic surgery

• Chairperson:
  Mitsuo ShimadaDepartment of Surgery, Tokushima University
• Chairperson:
  Go WakabayashiDepartment of Surgery, Ageo Central General Hospital
• Discussant:
  Ho-Seong HanDepartment of Surgery, Seoul National University Bundang Hospital

IS-S5-1_S
Withdrawn

IS-S5-2_S
The Glissonian pedicle approach and short-term outcomes of the laparoscopic anatomical liver resection

IS-S5-3_S
Impact of laparoscopic parenchyma-sparing resection of posterosuperior segments of the liver on surgical outcomes: a multicenter study based on propensity score analysis

IS-S5-4_S
The standardization and trouble shooting in laparoscopic liver resection.

IS-S5-5_S
Pancreatic division at neck reduces pancreatic fistula after laparoscopic distal pancreatectomy compared to at body

IS-S5-6_S
Semiderotation technique for robotic pancreaticoduodenectomy

IS-S5-7_S
Standardization of robotic pancreaticoduodenectomy

International Session (Symposium)6 (JSGS, JSGE, JGES, JSH)

Activities of multi-institutional clinical study in Asia

• Chairperson:
  Yuko KitagawaDepartment of Surgery, Keio University School of Medicine
• Chairperson:
  Masanori TerashimaDivision of Gastric Surgery, Shizuoka Cancer Center
• Discussant:
  Han-Kwang YangDepartment of Surgery, Seoul National University Hospital

IS-S6-1_E
Multi-center Randomized Controlled Trial of Gastric Endoscopic Submucosal Dissection with or without Epinephrine Added Solution Young Award

IS-S6-2_G
Multicenter, randomized controlled trial of long tube versus nasogastric tube with water-soluble contrast agent for adhesive small bowel obstruction

IS-S6-3_G
Effect of endoscopic biliary drainage with/without endoscopic sphincterotomy on post-ERCP pancreatitis in patients with biliary stricture (E-BEST): a multicenter randomized controlled trial

IS-S6-4_S
Activities in Gastrointestinal Endoscopy Study Group of Japan Clinical Oncology Group (JCOG-GIESG)

IS-S6-5_S
Multicenter clinical trials for esophageal cancer.

IS-S6-6_S
Experiences of clinical trials for colorectal cancer

IS-S6-Special Remarks